(Q42758536)

English

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

scientific article published on April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 November 2017

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

6 November 2017

type 2 diabetes

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

S Kasichayanula

1

1 reference

Europe PubMed Central

6 November 2017

M Chang

2

1 reference

Europe PubMed Central

6 November 2017

M Hasegawa

3

1 reference

Europe PubMed Central

6 November 2017

X Liu

4

1 reference

Europe PubMed Central

6 November 2017

N Yamahira

5

1 reference

Europe PubMed Central

6 November 2017

F P LaCreta

6

1 reference

Europe PubMed Central

6 November 2017

Y Imai

7

1 reference

Europe PubMed Central

6 November 2017

D W Boulton

8

1 reference

Europe PubMed Central

6 November 2017

publication date

1 April 2011

1 reference

Europe PubMed Central

6 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

6 November 2017

13

1 reference

Europe PubMed Central

6 November 2017

4

1 reference

Europe PubMed Central

6 November 2017

357-365

1 reference

Europe PubMed Central

6 November 2017

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Glucose control by the kidney: an emerging target in diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01359.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01359.X

1 reference

Europe PubMed Central

6 November 2017

release_ouzwgv6mtzddth5wghngx7uh3m

1 reference

https://api.fatcat.wiki/v0/release/ouzwgv6mtzddth5wghngx7uh3m

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

6 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42758536&oldid=2143946240"